Advanced NSCLC: What are the options?

An independent satellite symposium held in conjunction with the 17th European Congress:
Perspectives in Lung Cancer. Prague, Czech Republic

Chaired by Giorgio Scagliotti and Pieter Postmus

  • We are pleased to provide the Scientific Summary from this independent symposium, including slides and video presentations from the event.


    • Welcome and introduction – Pieter Postmus (UK)
    • Biopsy to guide personalised treatment – Erik Thunnissen (Netherlands)
    • Optimal treatment for the specific patient: case studies – Silvia Novello (Italy) and Fabrice Barlesi (France)
    • Current and future best practice for individualised care – All Faculty
    • Closing remarks – Giorgio Scagliotti (Italy)


    We also report on the panel discussion which addressed key topics such as:

    ALK FISH criteria – how well defined?
    EGFR T790M mutation – when to shift treatment?
    Second-line NSCLC therapy decisions and tumour morphology

    Please click on the image to access the Scientific Summary.

    PILC_2016-Scientific Summary THUMB


    Expert Interview


    Professors Giorgio Scagliotti and Pieter Postmus debate the highlights of the symposium and the future treatment paradigms for advanced and metastatic NSCLC arising from the emerging therapy options presented.
    Play video

  • Learning Objectives

    Following attendance at this symposium delegates are expected to:

    • Understand how best to use re-biopsy and liquid biopsy to guide therapy for advanced and metastatic NSCLC
    • Understand and demonstrate knowledge on how to best use the rapidly expanding and complex range of treatment options for the individual patient with advanced and metastatic NSCLC
    • Understand the emerging therapies for advanced and metastatic NSCLC and the future treatment paradigms they create
  • Dear Colleagues,

    Welcome to Prague, the ‘City of Spires’, and thank you for attending this satellite symposium ‘Advanced NSCLC: what are the options?’ at the Perspectives in Lung Cancer (PILC) congress. We hope you will find it engaging and informative.

    PILC provides a unique environment for a focused dialogue among experts in lung cancer. It is within this environment that we will provide a highly interactive learning experience for international Health Care Professionals (HCPs) that care for patients with advanced NSCLC. To address this goal the symposium will adopt a case-focussed approach with the aim of aiding attendees in confirming their current practices and optimizing their patient care.

    To this aim, we would encourage you to use the audience response technology to foster dialogue between the Faculty and symposium attendees. Via this technology, attendees will be able to vote on which treatment decisions they would make during the interactive case studies. These decisions will be used to stimulate discussion about what is current best practice for advanced NSCLC patients.

    The symposium will conclude with a Faculty panel discussion on the current and future best practice for individualised care. This will be a debate on the emerging therapies for the advanced and metastatic NSCLC patient and how clinicians can best operate within these new treatment paradigms and the resulting increased complexity in patient management. The therapy landscape for advanced NSCLC and, accordingly, the patient pathway through it, has greatly increased in complexity in recent years, so this discussion will provide a unique opportunity for attendees to discuss with the expert Faculty on how best to use the latest developments in therapy in their daily practice.

    We would be grateful if you would kindly provide your feedback by completing the evaluation form provided to you at the symposium. This will enable us to tailor future programme to your needs as HCPs treating patients with NSCLC.

    Yours faithfully,

    Pieter Postmus and Giorgio Scagliotti



    Giorgio V. Scagliotti, Torino, Italy

    Dr Scagliotti is currently Professor of Oncology at the University of Torino. Dr Scagliotti earned his medical degree and completed the postgraduate training in Respiratory Medicine, Internal Medicine, and Medical Oncology at the University of Torino.  He is currently Chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino) and Head of the Department of Oncology at the University of Torino.

    Dr Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. From 2003–2007 he was an Executive Board member of the International Association for the Study of Lung Cancer. He is also Associate Editor for Journal of Thoracic Oncology, International Editor for Clinical Lung Cancer and the author or co-author of more than 280 publications in peer-reviewed journals. Alongside this, he is the International Editor of the 4th Edition of “Lung Cancer: Principles and Practice” and co-editor of the International Association for the Study of Lung Cancer (IASLC) textbook Multidisciplinary Approach to Thoracic Oncology.

    Pieter E. Postmus, Liverpool, UK

    Professor Postmus was born in 1951 and obtained his MD at the University of Groningen in 1976. He trained as a pulmonologist in the University Hospital of Groningen from 1977–1981 and has worked in the field of thoracic oncology since 1978.

    He defended his doctorate thesis “New approaches in small cell lung cancer” in 1985 and became Associate Professor in the Department of Pulmonary Diseases at the University Hospital of Groningen from 1989–1992.

    Professor Postmus was Head Of Department and Professor of Pulmonary Diseases from 1992–2014 in Amsterdam. He was also a board member of (IASLC) from 2003 to 2011 and President of the World Conference on Lung Cancer (WCLC) 2011, held in Amsterdam.

    Since March 2015 he has been Professor of Thoracic Oncology in Liverpool. His research in thoracic oncology focuses on early detection, endobronchial therapy, staging procedures, testing and introducing new drugs and new combinations, and methods to communicate and inform patients and relatives.


    Silvia Novello, Turin, Italy

    Professor Novello graduated in Medicine from The University of Turin, Italy in 1995. She then did a Postgraduate Course in Respiratory Medicine. In 2006 she achieved a PhD in Human Oncology and went on to do a Postgraduate in Medical Oncology.

    In the past she has worked at S. Luigi Hospital, Clinic of Respiratory Diseases, Turin; the Institut Gustave Roussy, Villejuif, France and Thoracic Oncology Division, University of Turin. Now, she is Assistant Professor of Respiratory Medicine at The University of Turin, Department of Clinical and Biological Sciences, where her main area of research is based on the aspects of basic research and applied clinical research concerning bronchogenic carcinoma.

    She has been involved in trials and studies in different lung cancer and pleural mesothelioma clinical stages including among others: supportive care, the treatment of lung cancer in elderly patients, the role of cytokines in thoracic malignancies (lung cancer, pleural mesothelioma), the role of oncogenes, antioncogenes, growth factors and their receptors in lung cancer (pathogenesis, prognosis), women and lung cancer, pharmacogenomics and lung cancer and applied clinical research aspects regarding interstitial lung disease.

    Professor Novello is a Member of the American Society of Clinical Oncology (ASCO), Member of “Innovators in Lung Cancer”, Member of IASLC and Board of Director Member since July 2011, Member of NLCP (National Lung Cancer Partnership) Scientific Committee, Member of IASLC Young Investigators Awards Scientific Committee, BOD IASLC from 2011 until 2015 and President of the European Association – Women Against Lung Cancer in Europe (WALCE).

    Fabrice Barlesi, Marseille, France

    Fabrice Barlesi is Professor of Medicine and Head of the Multidisciplinary Oncology and Therapeutic Innovations department at Aix Marseille University, France. He also coordinates the Marseille’s Early Phase Cancer Trials Centre dedicated to phases I in oncology. His main clinical interests lie in research in lung cancer especially in the field of angiogenesis, bioguided therapies and immuno-oncology (as a part of Marseille’s Immunopole).

    Erik Thunnissen, Amsterdam, Netherlands

    Erik Thunnissen is consultant pathologist and staff member in the Department of Pathology, VUmc, Amsterdam a focus on Pulmonary Pathology. He is a long standing member of the IASLC pathology committee, leading reproducibility studies of the WHO classification for lung cancer and has taken responsibility for pulmonary molecular external quality assessment (EQA) programs in the Netherlands and for the European Society of Pathology.